Hikma reiterates guidance as currency headwinds weigh on interims
19th Aug 2015 08:03
(ShareCast News) - Hikma Pharmaceuticals reiterated its full-year guidance, although strong currency headwinds weighed on its interim pre-tax profit. The FTSE 100 group said it expected full-year revenue to grow approximately 6% year-on-year at constant currency or around 2% at actual exchange rates
Read moreLondon close: UK equities close week lower after non-farms, BoE's 'Super Thursday'
7th Aug 2015 16:13
(ShareCast News) - A worse-than-expected US non-farm payrolls report and the Bank of England's downward revision to inflation estimates dragged UK equities lower at close of trading on Friday. The US added 215,000 jobs in July, falling short of forecasts of 225,000, according to the Labor Department
Read moreLondon open: UK stocks decline ahead of US non-farm payrolls
7th Aug 2015 08:38
(ShareCast News) - UK stocks were in the red on Friday as investors continued to process news from the Bank of England and look ahead to the all-important US non-farm payrolls report. BoE Governor Mark Carney on Thursday said the timing of a first interest rate hike was drawing closer but the exact
Read moreBroker tips: Greene King, Hikma Pharmaceuticals
29th Jul 2015 18:33
(ShareCast News) - Goldman Sachs reinstated its 'buy' rating on Greene King with a 1,060p price target, saying it expects the company to deliver consistent earnings growth given its exposure to accelerating UK consumer discretionary spending, execution of synergies post its Spirit acquisition and in
Read moreFTSE 100 movers: GSK and Hikma lead blue chips higher
29th Jul 2015 15:24
(ShareCast News) - The FTSE 100 index built an early lead on Wednesday and stayed in positive territory thanks to forecast-busting results from several heavyweights in the pharma, tobacco and banking sectors. London's blue chip index was up 0.57% to 6,592.54 at 1435 BST. Top of the leaderboard mid-
Read moreJefferies ups Hikma to 'buy', says Roxane deal is a "game changer"
29th Jul 2015 11:44
(ShareCast News) - Hikma Pharmaceuticals got a boost after Jefferies upgraded the stock to 'buy' from 'hold' and raised its price target to 2,615p from 2,134p as it integrates the company's "transformational" deal with Roxane Laboratories. "In our view Hikma is transitioning to a period of remarkabl
Read moreLondon close: Investors play it safe ahead of Fed meeting
28th Jul 2015 17:56
(ShareCast News) - The selling pressure let up ahead of the start of a two-day policy meeting from the US Federal Reserve, with some investors braced in case the post-meeting statement sprang any surprises. The FTSE 100 finished the session higher by 0.77% to the 6,555.28 mark, alongside a similar b
Read moreFTSE 100 movers: RSA rockets, Hikma higher
28th Jul 2015 14:35
(ShareCast News) - London's primary index was holding onto its gain by mid-afternoon on Tuesday, boosted by deals and deal talk. At 1415 BST, the FTSE 100 was up 0.81% to 6,557.62, with only a dozen of the blue chip constituents in the red. As soon as markets opened, RSA Insurance moved to the top
Read moreLondon open: Stocks bounce even as analysts warn on emerging markets
28th Jul 2015 09:42
(ShareCast News) - The selling pressure on stocks abated as investors waited on the US Federal Reserve's policy announcement on Wednesday, but worries regarding the outlook for China, Greece and the possibility of interest rate increases were still very much on investors' minds. As of 08:47 the FTSE
Read moreHikma Pharmaceuticals acquires US labs in $2.25bn deal
28th Jul 2015 08:28
(ShareCast News) - Drug developer Hikma Pharmaceuticals signed a deal to buy two firms from Boehringer Ingelheim in transactions worth a total of $2.25bn. FTSE 100 listed Hikma planned to buy Roxane Laboratories and associated company Boehringer Ingelheim Roxane in a cash and shares deal that would
Read moreBroker tips: GlaxoSmithKline, Astrazeneca, Hikma, Shire, Petrofac, ARM Holdings
26th Jun 2015 11:39
HSBC initiated coverage of the European pharmaceuticals, saying the re-rating over the last few years looks set to continue. In terms of UK stocks, it initiated GlaxoSmithKline at 'buy' with a 1,700p price target, and AstraZeneca and Hikma Pharmaceuticals at 'hold' with 4,640p and 1,936p price targe
Read moreHSBC initiates coverage of European pharmaceuticals Astra, GSK, Hikma and Shire
26th Jun 2015 07:51
HSBC initiated coverage of the European pharmaceuticals, saying the re-rating over the last few years looks set to continue. Although some pharma companies, such as AstraZeneca, still face generic pressure for drugs that contribute significantly to their top and bottom lines, the majority are largel
Read moreLondon close: Stocks finish flat as optimism fades, Greek uncertainty persists
19th Jun 2015 17:06
UK stocks erased gains by the close on Friday with investors turning cautious ahead of the weekend, as ongoing uncertainty in Greece eroded earlier optimism. The FTSE 100 finished just 2.57 points higher (+0.04%) at 6,710.45, pulling back after hitting a high of 6,759.29 early on. Markets had opene
Read moreFTSE 100 movers: Hikma surges on upgrade, miners retreat
19th Jun 2015 13:50
UK stocks inched higher on Friday, despite an underwhelming outcome to the Eurogroup's meeting on Greece, with Hikma and Ashteadin the lead after broker upgrades. As of 15:00 BST, the FTSE 100 was trading 0.1% higher at 6,714. Pharmaceuticals group Hikma was a high riser after analysts at Citigroup
Read moreBroker tips: BP, Hikma, Kingfisher, Berkeley Group, PZ Cussons
19th Jun 2015 11:32
RBC Capital Markets downgraded BP to' sector perform' from 'outperform' and kept the price target at 500p, following the stock's significant outperformance versus its closest peer Royal Dutch Shell. "We continue to see potential upside to BP's cost reduction potential, but feel the risk reward oppor
Read more